Abstract: The recovery of iodide from chemical process wastewater is accomplished by loading the wastewater containing iodide onto a strongly basic anion-exchange resin in free-base form; eluting the sorbed iodide from the resin with aqueous strong acid (e.g., hydrochloric acid); loading the iodide-rich cuts onto a weakly basic anion-exchange resin in free-base form; and eluting the sorbed iodide with aqueous base (e.g., sodium hydroxide). The recovered iodide typically has sufficient purity to permit its re-use in the chemical process.

Abstract: A fluid separation device and in-line orifice mixer system is disclosed. The fluid separation device utilizes a syringe, which is used for obtaining a fluid sample such as blood, in a centrifugation device, and further utilizes the syringe as a source of a separated fluid portion for storage and transfer for subsequent applications. The syringe containing the separated portion source and a second syringe containing a second source are connected to the in-line orifice mixer device. The mixer device comprises a plurality of orifice walls each providing an orifice non-aligned with adjacent orifices to homogeneously mix the plurality of components. The mixer device may further comprise an exit orifice wall with one or more orifices for discharge of the homogeneous mixture.

Abstract: The present invention is directed to a solid poly-amphiphilic polymer. The polymer may be (1) a continuous film (a) which is strengthened sufficiently by cross-linking to be used alone and/or supported on a frame, (b) overlaid and/or cast on a porous hydrophobic support or (2) introduced into the pores of a microporous hydrophobic membrane. The present invention is also a process for selectively removing a dissolved species (solute or target compound) from an aqueous solution or from a gaseous stream comprising contacting said aqueous solution or gaseous stream having the dissolved species and an aqueous stripping solution or other means for removing said species with opposite sides or surfaces.

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.

Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.

Abstract: There is disclosed a slow release drug delivery device for the prolonged administration of topically active medicines which consists of a vehicle in which water is soluble and in which is dissolved the topically active drug which is formed into a stable organogel with a polymer matrix with a very low water absorbing capability. The organogel, in the presence of water or atmospheric water vapor, slowly imbibes such water into the vehicle and by doing so the vehicle becomes incompatible with the matrix and is slowly expelled therefrom. The vehicle dissolves the drug and the vehicle/drug combination is slowly pumped out of the polymeric matrix with substantially linear drug delivery occurring for periods in excess of 6 months. The drug delivery device may be used to administer drugs topically, as a collar or trans dermal patch, orally, as a slow delivery device, particularly as a ruminal bolus, or as a suppository or a subcutaneous implant.

Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.

Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding biologically inactive, natural, biocompatible polymer to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide biocompatible conjugates. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living (preferably human) being for the purpose of providing soft tissue augmentation.

Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.

Abstract: A process is provided for sterilizing or pasturizing aqueous fluids by contacting the aqueous fluid with a permeable membrane to separate the fluid into a serum and a residue, separating the serum into two portions, the pH of the first portion is increased and the pH of the second is decreased. The second portion of serum is combined with the residue, maintained at an elevated temperature to reduce the concentration of microbial cells, and combined with the first portion of serum to reconstitute the flowable fluid with a reduced concentration of viable cells.

Abstract: A process is described for the separation and recovery of phosphorus from phosphorus-dirt mixtures by adding a quaternary ammonium compound to the mixture, while it is under an aqueous cover, agitating same, and separating a lower phosphorus phase from an upper dirt phase. The mixtures are treated prior to addition of the quaternary ammonium compound, where required, by lowering their dirt to phosphorus levels sufficiently low to permit them to be destabilized.

Abstract: A hollow fiber membrane bioreactor process for continuous selective removal of organic toxicants or other oleophilic solutes present in an aqueous process stream wherein low concentration levels of said toxicant are removed from the aqueous process stream by being extracted and concentrated by the permeably selective hollow fiber membrane and then provided to a microorganism for metabolization into a water soluble metabolite. The water soluble metabolite is prevented from reentering the aqueous process stream and removed from the bioreactor in the aqueous nutrient effluent stream.

Abstract: An improved method and electrolytic cell for the oxidation of nitrogen-containing waste materials in a dialysate stream used for hemodialysis, hemofiltration or peritoneal dialysis comprises a cylinder having a porous anode and a porous cathode spaced apart in the direction of flow. By flowing the spent dialysate in the direction from the anode to the cathode, and applying sufficient voltage to oxidize chloride ion present to activated chlorine, the waste materials are oxidized to chlorinated intermediates. In the vicinity of the cathode, the chlorinated intermediates react further to yield to nitrogen and carbon dioxide, with the chlorine being reduced back to chloride ion. In this way, the dialysate is regenerated without the net evolution of undesirable chlorine species.